The device met the end points in the six-month, single-arm, 108-patient study.

The device features flow diversion in which the pipeline device disrupts the flow of blood from the parent artery into the aneurysm, and re-endothelialization where the device forms a scaffold upon which endothelial cells can grow.

The Pipeline Embolization device has obtained premarket approval in April 2011 and is indicated for the endovascular treatment of adults who are aged 22 years or older.